Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

31 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.
Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX. Kometer M, et al. Biol Psychiatry. 2012 Dec 1;72(11):898-906. doi: 10.1016/j.biopsych.2012.04.005. Epub 2012 May 10. Biol Psychiatry. 2012. PMID: 22578254 Clinical Trial.
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.
Vollenweider FX, Kometer M. Vollenweider FX, et al. Among authors: kometer m. Nat Rev Neurosci. 2010 Sep;11(9):642-51. doi: 10.1038/nrn2884. Epub 2010 Aug 18. Nat Rev Neurosci. 2010. PMID: 20717121 Review.
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.
Studerus E, Kometer M, Hasler F, Vollenweider FX. Studerus E, et al. Among authors: kometer m. J Psychopharmacol. 2011 Nov;25(11):1434-52. doi: 10.1177/0269881110382466. Epub 2010 Sep 20. J Psychopharmacol. 2011. PMID: 20855349 Clinical Trial.
The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations.
Kometer M, Cahn BR, Andel D, Carter OL, Vollenweider FX. Kometer M, et al. Biol Psychiatry. 2011 Mar 1;69(5):399-406. doi: 10.1016/j.biopsych.2010.10.002. Epub 2010 Dec 3. Biol Psychiatry. 2011. PMID: 21126732
Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.
Quednow BB, Kometer M, Geyer MA, Vollenweider FX. Quednow BB, et al. Among authors: kometer m. Neuropsychopharmacology. 2012 Feb;37(3):630-40. doi: 10.1038/npp.2011.228. Epub 2011 Sep 28. Neuropsychopharmacology. 2012. PMID: 21956447 Free PMC article. Clinical Trial.
Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.
Schmidt A, Bachmann R, Kometer M, Csomor PA, Stephan KE, Seifritz E, Vollenweider FX. Schmidt A, et al. Among authors: kometer m. Neuropsychopharmacology. 2012 Mar;37(4):865-75. doi: 10.1038/npp.2011.261. Epub 2011 Oct 26. Neuropsychopharmacology. 2012. PMID: 22030715 Free PMC article. Clinical Trial.
Prediction of psilocybin response in healthy volunteers.
Studerus E, Gamma A, Kometer M, Vollenweider FX. Studerus E, et al. Among authors: kometer m. PLoS One. 2012;7(2):e30800. doi: 10.1371/journal.pone.0030800. Epub 2012 Feb 17. PLoS One. 2012. PMID: 22363492 Free PMC article. Clinical Trial.
The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions.
Schmidt A, Kometer M, Bachmann R, Seifritz E, Vollenweider F. Schmidt A, et al. Among authors: kometer m. Psychopharmacology (Berl). 2013 Jan;225(1):227-39. doi: 10.1007/s00213-012-2811-0. Epub 2012 Jul 27. Psychopharmacology (Berl). 2013. PMID: 22836372
Modeling ketamine effects on synaptic plasticity during the mismatch negativity.
Schmidt A, Diaconescu AO, Kometer M, Friston KJ, Stephan KE, Vollenweider FX. Schmidt A, et al. Among authors: kometer m. Cereb Cortex. 2013 Oct;23(10):2394-406. doi: 10.1093/cercor/bhs238. Epub 2012 Aug 8. Cereb Cortex. 2013. PMID: 22875863 Free PMC article.
Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.
Kometer M, Schmidt A, Jäncke L, Vollenweider FX. Kometer M, et al. J Neurosci. 2013 Jun 19;33(25):10544-51. doi: 10.1523/JNEUROSCI.3007-12.2013. J Neurosci. 2013. PMID: 23785166 Free PMC article. Clinical Trial.
31 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback